A threshold inequality aversion parameter (TIAP) approach to interpret distributional cost-effectiveness analysis results

Pandya A, Zhu J, Luviano A, James LP, Goshua G

Cost-effectiveness of upfront vs. delayed allogeneic hematopoietic stem cell transplant for intermediate risk AML

Alhajahjeh A, Patel K, Podoltsev NA, Kewan T, Stempel JM, Mendez LM, Seropian SE, Gowda L, Huntington SF, Stahl MF, Zeidan AM, Goshua G* and Bewersdorf JP*

A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry

Pine A, Butt A, Andreoli L, Knight JS, Gerosa M, Cecchi I, Branch DW, Lopez-Pedrera R, Belmont HM, Kello N, Petri M, Cervera R, Pengo V, Meroni PL, Cohen H, Willis R, Bertolccini ML, Goshua G, Gu S, Hwa J, Lee AI, Erkan D, Sharda AV

Modeling the budgetary impacts of sickle cell disease gene therapies on state Medicaid programs

Harvey JP, Raymakers AJN, Rand LZ, Goshua G, Kesselheim AS, Pandya A

Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis

Glaeser-Khan S, Ito S, Sra M, Richmond R, Bona RD, Krumholz H, Croteau SE, Cuker A, Goshua G

Prophylactic weekly efanesoctocog alfa versus standard-care factor VIII in people living with severe hemophilia A: a cost-effectiveness analysis

Ito S, Potnis KC, Harvey JP, Sra M, Bewersdorf JP, Bona RD, Krumholz HM, Cuker A, Pandya A, Goshua G

Anchoring the Hemophilia Joint Health Score for conventional value assessment in the care of people living with severe hemophilia A

Ito S, Sra M, Goshua G

Cost-effectiveness of Lynch syndrome screening in colorectal cancer: universal germline vs sequential screening

Ito S, Xicola RM, Sra M, Potnis KC, Singh V, Gershkovich P, Stites E, Gibson J, Krumholz HM, Llor X, Goshua G